---
title: 'Revolutionizing <em>in vivo</em> therapy with CRISPR/Cas genome editing: breakthroughs,
  opportunities and challenges'
date: '2024-02-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38362491/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240216170700&v=2.18.0
source: heidelberg[Affiliation]
description: Genome editing using the CRISPR/Cas system has revolutionized the field
  of genetic engineering, offering unprecedented opportunities for therapeutic applications
  in vivo. Despite the numerous ongoing clinical trials focusing on ex vivo genome
  editing, recent studies emphasize the therapeutic promise of in vivo gene editing
  using CRISPR/Cas technology. However, it is worth noting that the complete attainment
  of the inherent capabilities of in vivo therapy in humans is yet to be ...
disable_comments: true
---
Genome editing using the CRISPR/Cas system has revolutionized the field of genetic engineering, offering unprecedented opportunities for therapeutic applications in vivo. Despite the numerous ongoing clinical trials focusing on ex vivo genome editing, recent studies emphasize the therapeutic promise of in vivo gene editing using CRISPR/Cas technology. However, it is worth noting that the complete attainment of the inherent capabilities of in vivo therapy in humans is yet to be ...